Prevention and treatment of vivax malaria

被引：37

作者：

Baird J.K. ^{[1
]}

Schwartz E. ^{[1
]}

Hoffman S.L. ^{[1
]}

机构：

[1] ALERTAsia Foundation, Eijkman Institute for Molecular Biology, Menteng, Jakarta 10430

来源：

Current Infectious Disease Reports | 2007年 / 9卷 / 1期

关键词：

Malaria; Chloroquine; Falciparum Malaria; Quine; Vivax Malaria;

D O I：

10.1007/s11908-007-0021-4

中图分类号：

学科分类号：

摘要：

Plasmodium vivax is a significant public health threat throughout most of the tropics and to travelers to these regions. The infection causes a debilitating febrile syndrome that often recurs and in rare cases ends in death. The complex life cycle of the parasite compounds the difficulty of prevention and treatment, principally due to the phenomenon of relapse. Most commonly used drugs for preventing malaria fail to prevent late relapses by this parasite. Treatment requires dealing with both blood and liver stages. Since 1950, primaquine has been the only drug available for treatment of liver stages, and important clinical questions surround its appropriate use (ie, dosing, efficacy, safety, and tolerability). Likewise, chloroquine has been first-line therapy for vivax malaria since 1946, and the emergence of resistance to the drug further complicates therapeutic management decisions. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：39 / 46

页数：7

共 63 条

[1] Mendis K., Sina B.J., Marchesini P., Carter R., The neglected burden of Plasmodium vivax malaria, Am J Trop Med Hyg, 64, 1-2 SUPPL., pp. 97-106, (2001)
[2] Kochar D.K., Saxena V., Singh N., Et al., Plasmodium vivax malaria, Emerg Infect Dis, 11, pp. 132-134, (2005)
[3] Krotoski W.A., Collins W.E., Bray R.S., Et al., Demonstration of hypnozoites in sporozoite-transmitted Plasmodium vivax infection, Am J Trop Med Hyg, 31, pp. 1291-1293, (1982)
[4] Glynn J.R., Bradley D.J., Inoculum size, incubation period and severity of malaria. Analysis of data from malaria therapy records, Parasitology, 110, PART 1, pp. 7-19, (1995)
[5] Church L.W., Le T.P., Bryan J.P., Et al., Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge, J Infect Dis, 175, pp. 915-920, (1997)
[6] Cogswell F.B., The hypnozoite and relapse in primate malaria, Clin Microbiol Rev, 5, pp. 26-35, (1992)
[7] Schwartz E., Praise M., Kozarsky P., Cetron M., Delayed onset of malaria: In travelers: Implications for chemoprophylaxis, N Engl J Med, 349, pp. 1510-1516, (2003)
[8] Hemmer C.J., Holst F.G., Kern P., Et al., Stronger host response per parasitized erythrocyte in Plasmodium vivax or ovale than in Plasmodium falciparum malaria, Trop Med Int Health, 11, pp. 817-823, (2006)
[9] Ravichandiran K., Sumitha K., Selvam R.J., Liver function tests in recurrent P. vivax malaria, Commun Dis, 28, pp. 231-240, (1996)
[10] Lomar A.V., Vidal J.E., Lomar F.P., Et al., Acute respiratory distress syndrome due to vivax malaria: Case report and literature review, Braz J Infect Dis, 9, pp. 425-430, (2005)

← 1 2 3 4 5 6 7 →